Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: Dr Bernadett Szabados

Back to Search
Leone G, Shokri A, Szabados BE, Khoo V, Crabb S, Enting D, Powles TB, Ottensmeier CHH et al. ( 2024 ) . 273MO DURANCE: A phase Ib/II study to assess the safety and activity of durvalumab (MEDI4736) in combination with S-488210/S-488211 vaccine in non-muscle invasive bladder cancer . Annals of Oncology vol. 35 , s1509 - s1510 .
Tippu Z, Lim KHJ, Hubank M, Zelenay S, Lawley T, Strange A, Corrie PG, Szabados BE et al. ( 2024 ) . 40P MANIFEST: A multiomic profiling platform for immuno-oncology biomarker discovery . Immuno-Oncology Technology vol. 24 ,
Aghababazadeh FA, Alonso L, López-de-Castro M, Guinot F, Desponds J, Furger S, Karapetyan A, Ott SI et al. ( 2024 ) . 1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy . Conference: Regular and Young Investigator Award Abstractsa1334 - a1337 .
Bickley LJ, Yang Y-H, Jackson-Spence F, Toms C, Sng C, Flanders L, Bex A, Powles T et al. ( 2024 ) . Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens . World Journal of Urology vol. 42 , ( 1 )
Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, Powles T, Szabados B ( 2024 ) . Renal cell carcinoma . The Lancet vol. 404 , ( Diagn Pathol 10 2015 ) 476 - 491 .
Jackson-Spence F, Ackerman C, Jones R, Toms C, Jovaisaite A, Young M, Hussain S, Protheroe A et al. ( 2024 ) . Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel . Urologic Oncology Seminars and Original Investigations vol. 42 , ( 11 ) 372.e1 - 372.e10 .
Nathan P, Venugopal B, Ali J, Allison J, Ceruso M, Charnley N, Griffiths R, Michael A et al. ( 2024 ) . Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results . Clinical Genitourinary Cancer vol. 22 , ( 5 )
Takemura K, Yuasa T, Lemelin A, Ferrier E, Wells JC, Saad E, Saliby RM, Basappa NS et al. ( 2024 ) . Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium ☆ . ESMO Open vol. 9 , ( 7 )
Szabados B, Powles T ( 2024 ) . On the Road Towards Curing Advanced Bladder Cancer . European Urology Focus vol. 10 , ( 2 ) 213 - 214 .
Hasakioğulları İ, Kockx M, Szabados B, Young M, Powles T ( 2024 ) . Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) 4584 - 4584 .
Chauhan V, Diaz SS, Jara P, Efovi D, Gurung A, Young M, Wells C, Nally E et al. ( 2024 ) . Abstract B013: Novel prognostic score for patients with metastatic bladder cancer on immunotherapy . Clinical Cancer Research vol. 30 , ( 10_Supplement ) b013 - b013 .
de Jong JJ, Reike M, Szabados B, Hakansson A, Necchi A, Powles T, Gibb E ( 2024 ) . PD14-05 THE STROMA-RICH CONSENSUS BLADDER CANCER SUBTYPE CORRELATES WITH IMPROVED PROGNOSIS AFTER NEOADJUVANT IMMUNOTHERAPY AND RADICAL CYSTECTOMY . Journal of Urology vol. 211 , ( 5S )
Nally E, Young M, Chauhan V, Wells C, Szabados B, Powles T, Jackson-Spence F ( 2024 ) . Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge . Cancer Management and Research vol. 16 , ( 0 ) 467 - 475 .
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP et al. ( 2024 ) . ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma . Annals of Oncology vol. 35 , ( 6 ) 485 - 490 .
Young M, Tapia JC, Szabados B, Jovaisaite A, Jackson-Spence F, Nally E, Powles T ( 2024 ) . NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors . Clinical Genitourinary Cancer vol. 22 , ( 3 )
De Jong JJ, Reike M, Szabados B, Hakansson A, Necchi A, Powles T, Gibb E ( 2024 ) . A0156 The stroma-rich consensus bladder cancer subtype correlates with improved prognosis after neoadjuvant immunotherapy and radical cystectomy . European Urology vol. 85 ,
Day E, Aquilina R, Ta A, Sridhar AN, Kelly JD, Szabados BE ( 2024 ) . A0363 Real-world outcomes of Bladder Sparing Treatments (BSTs) in patients with high-risk non-muscle invasive bladder cancer, who failed or were intolerant to BCG therapy . European Urology vol. 85 , s1180 - s1181 .
Diaz SS, Chauhan V, Gurung A, Nally E, Young M, Wells C, Jackson-Spence F, Szabados B et al. ( 2024 ) . A0745 Analysing resistance and progression patterns to immune checkpoint inhibitors in urothelial carcinoma . European Urology vol. 85 ,
Rijnders M, Nakauma-González JA, Robbrecht DGJ, Gil-Jimenez A, Balcioglu HE, Oostvogels AAM, Aarts MJB, Boormans JL et al. ( 2024 ) . Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer . Nature Communications vol. 15 , ( 1 )
Jackson-Spence F, Chauhan V, Silva Diaz S, Gurung A, Young MN, Nally E, Wells C, Szabados B et al. ( 2024 ) . Identification of patients with metastatic urothelial cancer not able to receive maintenance avelumab . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 702 - 702 .
Takemura K, Lemelin A, Ernst MS, Wells JC, Saliby RM, El Zarif T, Labaki C, Basappa NS et al. ( 2024 ) . Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium . European Urology vol. 86 , ( 6 ) 488 - 492 .
Young MN, Szabados B, Assaf Z, Jackson-Spence F, Nally E, Wells C, Suárez C, Castellano D et al. ( 2024 ) . Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 534 - 534 .
Jackson-Spence F, Young M, Jovaisaite A, Szabados B, Powles T ( 2024 ) . Adjuvant Therapy in Renal Cell Cancer . Kidney Cancer vol. 8 , ( 1 ) 17 - 22 .
Aquilina R, Ta A, Sridhar A, Kelly J, Szabados B, Day E ( 2024 ) . Real World Outcomes of Bladder Sparing Approaches in BCG Failure - A Single Centre Experience . European Journal of Surgical Oncology vol. 50 , ( 1 )
Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell T, Fife K, Griffiths R, Sharma A et al. ( 2023 ) . Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM) . Journal of Clinical Oncology vol. 42 , ( 3 ) 312 - 323 .
Takemura K, Ernst MS, Navani V, Wells JC, Bakouny Z, Donskov F, Basappa NS, Wood LA et al. ( 2023 ) . Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium . European Urology Oncology vol. 7 , ( 3 ) 501 - 508 .
Schulz GB, Rodler S, Szabados B, Graser A, Buchner A, Stief C, Casuscelli J ( 2020 ) . Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers . Journal of Geriatric Oncology vol. 11 , ( 7 ) 1061 - 1066 .
Back to Search